Salvinorin A [(2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-furanyl)-dodecahydro-6a,10b-dimethyl-4,10-dioxo-2h-naphtho [2,1-c] 
general assumption was that this cationic amino charge on the opioid ligand would interact with the side chain carboxyl group of an aspartate residue located in transmembrane III of the opioid receptor (Surratt et al., 1994; Eguchi, 2004) . Given the lack of a basic nitrogen in Salvinorin A, this interaction is not an absolute requirement.
The pharmacology of Salvinorin A differs from that of other agonists . Although Salvinorin A and U50,488H stimulated [
35 S]GTP␥S binding with similar potency in Chinese Hamster ovary cells (CHO) expressing the cloned human receptor, salvinorin A was ϳ40-fold less potent than U50,488H in promoting receptor internalization. As observed with other agonists (Devine et al., 1993) , Salvinorin A produces decreases in extracellular dopamine in both mouse caudate (Zhang et al., 2005) and rat nucleus accumbens (Carlezon et al., 2006) .
Our initial binding studies showed that Salvinorin A weakly inhibited -and ␦-opioid receptor binding (Roth et al., 2002) , a finding replicated by others . In a subsequent report (Harding et al., 2005) , using the radioligand [
125 I]IOXY, we generated more detailed Salvinorin A inhibition curves and observed that Salvinorin A and certain other Salvinorin A analogs partially inhibited [
125 I]IOXY binding to the cloned human receptor expressed in CHO cells (hMOR-CHO cells) . In the present study, we characterized the interaction of Salvinorin A with -opioid receptors. We report evidence that Salvinorin A allosterically modulates -receptor binding.
Materials and Methods
Cell Culture and Membrane Preparation. The recombinant CHO cells (hMOR-CHO) were produced by stable transfection with the human opioid receptor cDNA and provided by Dr. Larry Toll (SRI International, Menlo Park, CA). The cells were grown on plastic flasks in Dulbecco's modified Eagle's medium/F-12 (50%/50%) medium (hMOR-CHO) containing 10% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.20 -0.25 mg/ml G-418 under 95% air/5% CO 2 at 37°C. Cell monolayers were harvested and homogenized using a Polytron grinding apparatus in 50 mM TrisHCl, pH 7.4, containing 4 g/ml leupeptin, 2 g/ml chymostatin, 10 g/ml bestatin, and 100 g/ml bacitracin, The homogenate was centrifuged at 15,000 rpm for 10 min at 4°C, and the supernatant was discarded. The membrane pellets were resuspended in binding buffer and used for [
35 S]GTP␥S binding assays. For drug pretreatment experiments, the medium was changed, and then cells were incubated with various test drugs for 20 h. Cells were washed three times with phosphate-buffered saline (pH 7.4), and cell membranes were prepared as described above. This treatment produces tolerance to opioid drugs (Xu et al., 2003) .
[ 35 S]GTP␥S Binding Assays. [ 35 S]GTP␥S binding was determined as described previously (Xu et al., 2001) . In brief, test tubes received the following additions: 50 l of buffer A (50 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, 10 mM MgCl 2 , and 1 mM EDTA), 50 l of GDP in buffer A (final concentration ϭ 50 M), 50 l of drug in buffer A/0.1% bovine serum albumin, 50 l of [
35 S]GTP␥S in buffer A (final concentration ϭ 50 pM), and 300 l of cell membranes (50 g of protein) in buffer B. The final concentrations of reagents in the [ 35 S]GTP␥S binding assays were: 50 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 1 mM dithiothreitol, and 0.1% bovine serum albumin. Incubations proceeded for 2 h at 25°C. Nonspecific binding was determined using GTP␥S (40 M).
Bound and free [
35 S]GTP␥S were separated by vacuum filtration through Whatman GF/B filters. The filters were punched into 24-well plates, to which 0.6 ml of liquid scintillation cocktail (Cytoscint; MP Biomedicals, Irvine, CA) was added. Samples were counted after an overnight extraction in a Trilux liquid scintillation counter at 60% efficiency.
Opioid Binding Assays. pH 7.4 , with a protease inhibitor cocktail [bacitracin (100 g/ml), bestatin (10 g/ml), leupeptin (4 g/ml), and chymostatin (2 g/ml)] in a final assay volume of 0.5 ml. Nonspecific binding was determined using 20 M levallorphan. Triplicate samples were filtered with Brandel cell harvesters (Biomedical Research and Development Inc., Gaithersburg, MD) over Whatman GF/B filters after a 2-to 3-h incubation at 25°C. For the [ 125 I]IOXY experiments, the filters were punched into 12 ϫ 75-mm glass test tubes and counted in a Micromedic gamma counter at 80% efficiency. For the 3 H-ligand binding assays, the filters were punched into 24-well plates, to which was added 0.6 ml liquid scintillation cocktail (Cytoscint). Samples were counted, after an overnight extraction, in a Trilux liquid scintillation counter at 44% efficiency. Opioid binding assays using membranes prepared from hMOR-CHO cells had ϳ30-g protein per assay tube.
Inhibition curves were generated by displacing a single concentration of radioligand by 10 concentrations of drug. For binding surface experiments (Rothman, 1986; Rothman et al., 1991) , two different concentrations of radioligand were each displaced by ten concentrations of nonradioactive ligand agents in the absence or presence of various blockers.
Cyclic AMP Assays. Functional coupling of the cloned -opioid receptor to adenylate cyclase was determined by measuring changes in the levels of cellular cAMP. The assay procedures followed the protocol provided by CatchPoint cyclic-AMP fluorescent assay kit (a horseradish peroxidase-based competitive immunoassay kit). For acute studies, hMOR-CHO cells were grown to 80 to 90% confluence in 96-well black-walled, clear bottom plates that had been treated with poly-L-lysine. After aspirating the medium, cells were washed with 300-l/well Krebs-Ringer bicarbonate buffer with glucose (KRBG, pH 7.4). KRBG containing 0.75 mM 3-isobutyl-1-methylxanthine and 1 mg/ml bovine serum albumin and appropriate agonists were added to each well (90 l). After a 30-min incubation at 37°C, 100 M forskolin in KRBG containing 0.75 mM 3-isobutyl-1-methylxanthine and 1 mg/ml bovine serum albumin was added to each well in a volume of 10 l. Cyclic AMP production was terminated 40 min later by the addition of 50 l of a cell-lysing solution (Molecular Devices, Sunnyvale, CA). For chronic studies, cells were grown to 80% confluence in 96-well black-walled, clear bottom plates (number 3603, Corning Inc., Corning, NY) that had been treated with poly-L-lysine. After treatment with medium or 10 M drug for 20 h, cells were rinsed three times with 300-l/well KRBG (pH 7.4) and assayed as described above. This assay was sensitive between 0.1 and 10 pmol of cAMP in a 40-l sample volume. A FlexStation II (Molecular Devices) was used to read and quantitate fluorescence intensity of the plate. Data from three experiments were analyzed using the program Prism (version 3.0; GraphPad Software, Inc., San Diego, CA). Results are presented as the mean Ϯ S.E.M.
Stimulation of p42/p44 MAPK Phosphorylation. The assay procedures followed the protocol provided by PhosphoPlus p44/42 MAPK (Thr202/Tyr204) antibody kit (Cell Signaling, Beverly, MA). In brief, cells were grown to 80 to 90% confluence in six-well plates. The assay started by the addition of any agonists and stopped after 5 min by rinsing the cells with ice-cold 1ϫ phosphate-buffered saline. Cells were lysed by adding SDS sample buffer (100 l) and immediately scraped to a microcentrifuge tube on ice, sonicated for 10 to 15 s, and boiled for 5 min. Samples (20 l) were loaded onto SDSpolyacrylamide gel electrophoresis gel as described previously (Xu et al., 2005) . Western blots were digitized and quantified using densitometric analysis (NIH Image software). Results from at least three experiments were analyzed using the program Prism. (Xu et al., 2004 The amount of cAMP in the samples was measured using a cAMP standard curve. Forskolin (100 M)-stimulated cAMP formation in the absence of agonist was defined as 100%. The EC 50 (the concentration of agonist that produces 50% inhibition of forskolin-stimulated cAMP formation) and E MAX (percentage of maximal inhibition of forskolinstimulated cAMP) were calculated using the program Prism.
In receptor binding experiments, for drugs that produced inhibition curves without apparent plateaus, the data were fit to the two-parameter logistic equation for the best-fit estimates of the IC 50 and n values (Nightingale et al., 2005) . For curves with apparent plateaus, the data were transformed to "percentage inhibition" and fit to a two-parameter dose-response curve model:
, for the best fit estimates of the E MAX and EC 50 using either KaleidaGraph version 3.6.4 or MLAB-PC (Nightingale et al., 2005) . Radioligand binding surfaces generated with [ 3 H]DAMGO or [ 3 H]diprenorphine were fit to onesite binding models using MLAB-PC as described elsewhere . Statistical significance among binding parameters was determined using the F-test . Dissociation experiments were conducted with minor modification of published procedures, in which the data were fit to a two-component dissociation model (de Costa et al., 1992; Ni et al., 1993) . The sources of other agents are published elsewhere (Xu et al., 2004) . Salvinorin A and herkinorin were synthesized as described previously (Harding et al., 2005) . For experiments using Salvinorin A or herkinorin, drug dilution curves were made up from freshly prepared 10 mM stock solutions in dimethyl sulfoxide. As is our standard operating procedure, all drug dilution curves used buffer with 1 mg/ml bovine serum albumin.
Results

Ligand Binding Experiments.
Our initial experiments demonstrated that Salvinorin A, whose structure is shown in Fig. 1 , partially inhibited [
125 I]IOXY (0.9 nM) binding to membranes prepared from hMOR-CHO cells (Fig. 1) , with an EC 50 value of 1728 nM and an E MAX value of 48%. Similar results were observed in rat brain membranes using [ 3 H]DAMGO to label receptors (Fig. 2) . In this case, Salvinorin A partially inhibited -receptor binding with an EC 50 value of 2322 nM and an E MAX value of 60%.
To further characterize Salvinorin A-mediated partial inhibition of -receptor binding, we generated Salvinorin A inhibition curves using three concentrations of [ 3 H]DAMGO (0.5, 2.0, and 8.0 nM) designed to produce varying levels of -receptor occupation (the K d is ϳ2 nM), using membranes prepared from hMOR-CHO cells. As reported in Fig. 3 Table 2 , Salvinorin A had complex actions on the K d and B max values in hMOR-CHO cells. Salvinorin A increased the K d value in a dose-dependent manner, producing a maximal increase to ϳ8.9 nM. After increasing the B max value at a concentration of 6400 nM, Salvinorin A proceeded to decrease the B max value at higher concentrations. These data, normalized as percentage changes, are reported in Fig. 5, A Table 3 , both 10,000 and 40,000 nM Salvinorin A decreased the B max value by ϳ34% and increased the K d by ϳ2-fold. Consistent with the plateau reported in Fig. 4 (Table 4) and that the addition of Salvinorin A to the DAMGO condition significantly increased the dissociation rate constant (K 2 ) of the faster-dissociating component. Salvinorin A significantly decreased (1.5-fold) the dissociation rate constant (K 1 ) of the slower-dissociating component, accounting for the apparent slower dissociation rate observed in this condition.
Hoping to conduct a dissociation experiment under conditions of a one-component dissociation model, we repeated this experiment using the antagonist [ 3 H]diprenorphine. These experiments were conducted at 37°C, because [
3 H]diprenorphine dissociation was too slow at 25°C. As reported in Fig. 7 and Table 5 , the addition of 10 M diprenorphine resulted in a fairly rapid dissociation that was best described by a twocomponent dissociation model. Salvinorin A alone (30 M) resulted in a much slower dissociation of [ 3 H]diprenorphine, an observation mainly accounted for by a decreased value of K 1 from 0.021 to 0.0025 min Ϫ1 (Table 5) . Interestingly, the addition of an approximate IC 50 concentration, (Ϫ)-U50,488 (1 M), produced a dissociation curve not significantly different from Salvinorin A. It is noteworthy that the diprenorphine ϩ Salvinorin A condition resulted in statistically significant changes in the kinetic parameters compared with the diprenorphine condition: decreased A 1 , decreased K 1 , and increased A 2 .
Functional Experiments. Using the [ 35 S]GTP␥S binding assay, we assessed the effect of Salvinorin A on measures of -receptor function. As reported in Fig. 8A and 53 Ϯ 8** 3.2 Ϯ 0.5* increase in the Salvinorin A concentration to 50 M should further increase the DAMGO ED 50 to 804 nM, such that the same K e value would result. However, 50 M Salvinorin A increased the DAMGO ED 50 only an additional 1.13-fold to 218 nM. In contrast, 10 nM naloxone, a competitive antagonist, increased the DAMGO ED 50 more than predicted based on its K e determined with a 2.5 nM dose. We determined the effect of Salvinorin A (50 M) and DAMGO (10 M) on basal and forskolin-stimulated cAMP levels. As reported in Fig. 9A , DAMGO and Salvinorin A did not alter basal cAMP levels. As expected, DAMGO almost completely inhibited forskolin-stimulated cAMP accumulation. Salvinorin A inhibited forskolin-stimulated cAMP accumulation by 44%. We compared the effect of naloxone (a competitive inhibitor) and Salvinorin A on DAMGO-mediated inhibition of forskolin-stimulated cAMP accumulation in the hMOR-CHO cells. As reported in Table 7 , 50 M Salvinorin A significantly increased the ED 50 value. The calculated apparent K e was 27 M. Salvinorin A also decreased the E MAX value by ϳ9%. In contrast, naloxone increased the ED 50 without decreasing the E MAX . Thus, in the cAMP assay, Salvinorin A demonstrated partial agonist activity.
The cellular adaptations produced by chronic opioids are generally accepted as signs of opioid dependence. We next determined the effect of Salvinorin A (50 M) on the cellular adaptations produced by chronic treatment of cells with DAMGO (10 M) and the novel -opioid agonist herkinorin (10 M) (Harding et al., 2005) . Cells were treated for 20 h with DAMGO or herkinorin in the absence and presence of Salvinorin A. We measured two endpoints: forskolin-stimulated cAMP, which detects cAMP superactivation, and naloxone-stimulated cAMP in the presence of forskolin, which detects the presence of constitutively active receptors. As reported in Fig. 9B , chronic DAMGO treatment produced cAMP superactivation without a naloxone overshoot. Chronic herkinorin treatment reduced forskolin-stimulated cAMP, but the addition of naloxone revealed the occurrence of cAMP superactivation and the presence of constitutively active receptors. Salvinorin A did not change the cellular response to either treatment. However, chronic Salvinorin A treatment produced signs of cAMP superactivation.
In contrast to the activity of Salvinorin A in functional assays that measured changes in the level of cellular cAMP, Salvinorin A was inactive in the MAPK assay, which is at ASPET Journals on July 9, 2017 jpet.aspetjournals.org
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activated by the G␤␥ subunit. As reported in Fig. 10 , DAMGO stimulated the phosphorylation of MAPK. Salvinorin A alone had no effect and did not alter the effect of DAMGO in this assay.
Discussion
As described in a recent review (Christopoulos and Kenakin, 2002) , allosteric modulators of G protein-coupled receptors may be of interest as potential targets for medication development. There are few reports of allosteric modulators of opioid receptors that we are aware of. In 1987, Vaysse et al. (1987) (Xu et al., 1991) .
In our recent article (Roth et al., 2002) , we briefly noted that Salvinorin A, a potent -opioid receptor agonist, partially inhibited [ 125 I]IOXY binding to -opioid receptors (see Table 1 in Harding et al., 2005) . In the present study, we tested the hypothesis that Salvinorin A allosterically modulates -opioid receptors. Several lines of evidence support this hypothesis. 1) Salvinorin A partially inhibits -receptor binding using both the cloned human receptor expressed in CHO cells, as well as the native receptor present in rat brain membranes. We observed a partial inhibition pattern with three radioligands: Figs. 3 and 4 , the presence of a plateau is most readily observed using radioligand concentrations sufficient to occupy a substantial fraction of receptors, such as 0.9 nM [ 125 I]IOXY (Fig. 1), 8 nM [ 3 H]DAMGO (Fig. 3) , or 0.5 nM [ 3 H]diprenorphine (Fig. 4) . The partial inhibition pattern we TABLE 4 Best-fit parameter estimates for ͓ 3 H͔DAMGO dissociation ͓ 3 H͔DAMGO (1.0 nM) dissociation curves were generated as described under Materials and Methods at 37 o C. The data of each experimental condition, generated with hMOR-CHO cell membranes, were pooled and fit using MLAB-PC to the two-component exponential decay model for the best-fit estimates reported above. Each value is the mean Ϯ S.D. (n ϭ 8 -12).
DAMGO ( observed, where the inhibition curve shifts to the right with a lower E MAX value as the radioligand concentration is increased, is consistent with the theoretical predictions made by Ehlert (1988) for negative allosteric modulators. This partial inhibition pattern is unique to Salvinorin A, because (Ϫ)-U50,488, a potent agonist, and naloxone, a competitive antagonist, produce "normal" inhibition curves without any evidence of a plateau.
2) Salvinorin A affects the K d and B max of the receptor in a manner inconsistent with competitive binding. Using [ 3 H]DAMGO and hMOR-CHO cells, Salvinorin A first increased the -receptor B max followed by highly significant decreases in the B max at higher concentrations. It is noteworthy that Salvinorin A increased the K d of the receptor in a dose-dependent manner (Fig. 5A ), rather than a linear manner, as would observed with a competitive inhibitor (Ehlert, 1988) . Thus, the ability of Salvinorin A to increase the K d reaches a ceiling at approximately 200% of control. Salvinorin A-mediated uncompetitive inhibition of -receptor binding was also observed in rat brain (Table 2 ) and in hMOR-CHO cells using [ 3 H]diprenorphine (Table 3) . 3) Salvinorin A alters the kinetics of radioligand dissocia- H͔Diprenorphine (0.1 nM) dissociation curves were generated as described under Materials and Methods at 37 o C. The data of each experimental condition, generated with hMOR-CHO cell membranes, were averaged and fit using KaleidaGraph 3.5 to the two-component exponential decay model for the best-fit estimates reported above. Each value is the mean Ϯ S.D. (n ϭ 4).
Condition
A
Diprenorphine ( Table 6 ). Each value is mean Ϯ S.D. (n ϭ 3). B, Salvinorin A antagonizes DAMGO-stimulated [
35 S]GTP␥S binding. Using membranes prepared from hMOR-CHO cells, DAMGO dose-response curves were generated in the absence and presence of various concentrations of Salvinorin A and naloxone. The data were pooled and analyzed for the best-fit estimates of the E MAX and ED 50 (see Table 6 ). Each value is the mean Ϯ S.D. (n ϭ 3). tion. It is well known that allosteric modulators can alter the rate of radioligand dissociation (Kostenis and Mohr, 1996) . As reported in (Fig. 7) , mainly by decreasing K 1 by more than 10-fold. Viewed in context with the other findings, such as the partial inhibition pattern, these data are consistent with an allosteric effect. However, the addition of a nonallosteric compound, (Ϫ)-U50,488, at an approximate IC 50 concentration resulted in a similarly slowed dissociation of (Fig. 8B) . As reported in Table 6 , Salvinorin A produced a dose-dependent decrease in the E MAX and failed to increase the ED 50 value significantly when the Salvinorin A concentration was increased from 10 to 50 M, as was observed for a competitive inhibitor, naloxone. We believe that these four lines of data support the hypothesis that Salvinorin A allosterically modulates -receptor binding and function.
The effects of Salvinorin A in the functional assays deserve additional study. For example, Salvinorin A stimulates [ 35 S]GTP␥S binding with low potency and an extrapolated jpet.aspetjournals.org
Downloaded from E MAX value of approximately 42% that of DAMGO. The simplest explanation of these data is that Salvinorin A is a weak partial agonist. This finding is supported by the ability of Salvinorin A to decrease forskolin-stimulated cAMP accumulation and to induce cAMP superactivation (Fig. 9) . However, naloxone noncompetitively inhibits Salvinorin A-stimulated [ 35 S]GTP␥S binding, suggesting that Salvinorin A acts at a site on the receptor distinct from that of typical ligands. This viewpoint is supported by point four in the previous paragraph and the fact that Salvinorin A, unlike DAMGO, had no activity in the MAPK assay (Fig. 10) . Viewed collectively, the functional data indicate that Salvinorin A may have some partial agonist activity at receptors in addition to the allosteric effects described above. Assuming that Salvinorin A has partial agonist activity at receptors, it might be possible to detect -mediated antinociception following administration of Salvinorin A. However, Salvinorin A-induced antinociception was not observed in receptor knockout mice (Ansonoff et al., 2006) , suggesting that the potency of Salvinorin A as a partial agonist is probably too low to produce detectable antinociception. The ultimate significance of this work remains to be seen. However, the immediate significance of our findings is the clear demonstration that the -opioid receptor possesses an allosteric modulator site. A major challenge of subsequent work will be to identify more potent ligands for the allosteric site. Toward this end, we note that certain analogs of Salvinorin A also partially inhibit -opioid receptors (Tidgewell et al., 2006) as well as ␦-opioid receptors (R. B. Rothman and T. E. Prisinzano, unpublished data). Thus, we anticipate that the Salvinorin A structural template will yield a number of allosteric modulators of opioid receptors. A more complete structure-activity profile of the allosteric site will be used to design more potent allosteric ligands. Once these are available, it will be possible to determine the in vivo effects and potential therapeutic application of allosteric modulators of -opioid receptors. It is possible, as observed with other classes of medications that work via allosteric mechanisms (benzodiazepines), that allosteric modulators of opioid receptors will have therapeutic value. Because a positive allosteric modulator will enhance the action of endogenous ligands acting via receptors, such a drug could produce analgesia with fewer adverse effects than that produced by direct -receptor agonists. Furthermore, it is unfortunate that we do not yet know the molecular basis of the allosteric actions of Salvinorin A at the -opioid receptor. Site-directed mutagenesis studies, such as those that delineated the interaction of Salvinorin A at the -opioid receptor (Yan et al., 2005) , will be necessary to definitively prove that the Salvinorin A-induced allosteric effects reported here are mediated via a binding site on the receptor distinct from the binding site of other ligands.
